TENX vs. BASI, IMMX, BRNS, PASG, BLRX, IOBT, ATRA, RLYB, DRRX, and PRPH
Should you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Bioanalytical Systems (BASI), Immix Biopharma (IMMX), Barinthus Biotherapeutics (BRNS), Passage Bio (PASG), BioLineRx (BLRX), IO Biotech (IOBT), Atara Biotherapeutics (ATRA), Rallybio (RLYB), DURECT (DRRX), and ProPhase Labs (PRPH). These companies are all part of the "medical" sector.
Bioanalytical Systems (NASDAQ:BASI) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.
Tenax Therapeutics has a consensus target price of $480.00, indicating a potential upside of 12,498.43%. Given Tenax Therapeutics' higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Bioanalytical Systems.
Tenax Therapeutics received 12 more outperform votes than Bioanalytical Systems when rated by MarketBeat users. Likewise, 55.78% of users gave Tenax Therapeutics an outperform vote while only 39.51% of users gave Bioanalytical Systems an outperform vote.
10.6% of Bioanalytical Systems shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 11.5% of Bioanalytical Systems shares are owned by company insiders. Comparatively, 0.3% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Bioanalytical Systems has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500.
In the previous week, Tenax Therapeutics had 3 more articles in the media than Bioanalytical Systems. MarketBeat recorded 3 mentions for Tenax Therapeutics and 0 mentions for Bioanalytical Systems. Tenax Therapeutics' average media sentiment score of 0.96 beat Bioanalytical Systems' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.
Tenax Therapeutics has a net margin of 0.00% compared to Bioanalytical Systems' net margin of -7.75%. Bioanalytical Systems' return on equity of -42.74% beat Tenax Therapeutics' return on equity.
Bioanalytical Systems has higher revenue and earnings than Tenax Therapeutics.
Summary
Tenax Therapeutics beats Bioanalytical Systems on 8 of the 14 factors compared between the two stocks.
Get Tenax Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenax Therapeutics Competitors List
Related Companies and Tools
